Invest in your career with a Madrona-funded company.

Envisagenics

envisagenics.com

Envisagenics is a pioneering company in RNA therapeutics development, utilizing Artificial Intelligence and Machine Learning to enhance drug discovery. Their flagship product, Splice Core®, is a cloud-based platform that identifies and validates drug targets derived from RNA splicing variations, achieving a 78% experimental validation rate. The company differentiates itself through its exon-centric approach, which allows for a 250x larger search space for target discovery compared to traditional methods. Founded in 2014 as a spinout from Cold Spring Harbor Laboratory, Envisagenics has established a strong market position with collaborations in the biopharma sector and a commitment to improving patient outcomes through innovative therapies.